Lisinopril Pediatric (Under 12) Dosing

FDA-Approved Age Range and Indications

Lisinopril carries FDA approval for treating hypertension in pediatric patients aged 6 years and older with a glomerular filtration rate (GFR) above 30 mL/min/1.73 m² [1]. The approval rests on a randomized, double-blind pediatric trial (N=115) published by Soffer et al. in 2003 that demonstrated dose-dependent blood pressure reduction in children aged 6 to 16 [2].

Children under 6 years old fall outside the labeled indication. No adequately powered trial has evaluated lisinopril in this age group, and the 2017 American Academy of Pediatrics (AAP) Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents acknowledges this evidence gap [3]. Prescribers who choose to use lisinopril off-label in children younger than 6 should do so only after consultation with a pediatric nephrologist or cardiologist, with documentation of the clinical rationale. The AAP guideline recommends ACE inhibitors as a first-line class for pediatric hypertension when pharmacotherapy is indicated, particularly in the presence of proteinuria or chronic kidney disease (CKD) [3].

Weight-Based Starting Dose Calculation

The recommended initial dose is 0.07 mg/kg given orally once daily [1]. That translates to practical numbers quickly. A 20 kg child starts at approximately 1.4 mg. A 30 kg child starts at approximately 2.1 mg. Because lisinopril tablets are scored but not available below 2.5 mg commercially, compounding a suspension (1 mg/mL concentration is standard) becomes necessary for precise weight-based dosing in smaller children [4].

The ceiling on the starting dose is 5 mg regardless of weight. A 70 kg adolescent still begins at 5 mg, not 4.9 mg calculated from body weight. This cap exists to limit first-dose hypotension, which ACE inhibitors can trigger through acute removal of angiotensin II-mediated vasoconstriction.

For clinical teams, a dosing ladder by weight band simplifies prescribing:

| Weight (kg) | Starting Dose | Titration Step | Maximum Dose | |---|---|---|---| | 15-19 | 1-1.5 mg | 2.5 mg | 9-12 mg | | 20-29 | 1.5-2 mg | 2.5-5 mg | 12-18 mg | | 30-39 | 2-2.5 mg | 5 mg | 18-24 mg | | 40-49 | 2.5-3.5 mg | 5 mg | 24-30 mg | | 50+ | 5 mg | 5-10 mg | 30-40 mg |

These values derive from the 0.07 mg/kg start and 0.61 mg/kg maximum in the FDA label [1].

Titration Schedule and Blood Pressure Targets

Dose increases should occur no more frequently than every 1 to 2 weeks [1]. The 2017 AAP guideline defines the treatment target as blood pressure below the 90th percentile for age, sex, and height in children without comorbidities, and below the 50th percentile for children with CKD or diabetes [3].

Each titration step roughly doubles the previous dose until the target or maximum is reached. The clinician should measure seated blood pressure at trough (approximately 24 hours post-dose) to assess adequacy of once-daily coverage. If trough blood pressure exceeds goal while peak blood pressure is controlled, splitting the dose into twice-daily administration is an off-label option supported by pharmacokinetic data showing a 12-hour half-life in some pediatric patients [2].

The Soffer et al. trial demonstrated a mean systolic reduction of 8.2 mmHg at the 0.6 mg/kg dose compared with placebo withdrawal [2]. This magnitude of reduction is clinically meaningful in pediatric patients, where stage 1 hypertension may begin just 4 mmHg above the 95th percentile.

Compounded Oral Suspension Preparation

Many children under 12 cannot swallow tablets. The FDA-approved labeling includes instructions for a 1 mg/mL oral suspension compounded from tablets [1]. The preparation uses Bicitra (sodium citrate/citric acid dihydrate solution) as the vehicle, combined with Ora-Sweet SF as a sweetening agent.

Stability data confirm the suspension retains potency for 4 weeks when stored at or below 25°C (77°F) [4]. Pharmacists should shake the bottle before each use and dispense with an oral syringe marked in 0.1 mL increments. Parents need clear written instructions specifying the exact volume in milliliters, not the dose in milligrams. A 20 kg child receiving 1.4 mg takes 1.4 mL of the 1 mg/mL suspension.

Commercially manufactured oral solutions of lisinopril are not currently available in the United States, making compounding the sole liquid option. This creates a practical barrier in communities without compounding pharmacies, which prescribers should address proactively by identifying available compounding services.

Renal Function and Electrolyte Monitoring

ACE inhibitors reduce intraglomerular pressure by dilating the efferent arteriole. This mechanism protects against long-term nephron loss in CKD but can acutely reduce GFR, particularly in patients with bilateral renal artery stenosis or volume depletion [5]. Baseline labs before starting lisinopril must include serum creatinine, blood urea nitrogen, and potassium.

Repeat these labs 1 to 2 weeks after initiation and after each dose increase [3]. A creatinine rise exceeding 30% from baseline warrants holding the dose and investigating volume status. Hyperkalemia (potassium above 5.5 mEq/L) requires dose reduction or discontinuation.

The ESCAPE trial (Effect of Strict blood pressure Control and ACE inhibition on the Progression of CRF in Pediatric patients, N=385) demonstrated that ramipril slowed GFR decline in children with CKD, with proteinuria reduction as the primary mediator of benefit [6]. While this trial used ramipril, the class effect extends to lisinopril for renoprotection in pediatric CKD with proteinuria. Monitoring urine protein-to-creatinine ratio every 3 to 6 months helps track therapeutic response.

Special Populations Within Pediatric Use

Neonates and Infants (Under 1 Year)

Lisinopril is contraindicated in neonates with a history of oligohydramnios exposure in utero. Even without prenatal exposure, ACE inhibitors carry substantial risk in neonates due to immature renal physiology. GFR at birth is approximately 20 mL/min/1.73 m² and does not reach adult values until age 2 [7]. The risk of acute kidney injury from ACE inhibition in this population is high.

Children with Single Functioning Kidney

Approximately 1 in 1,000 children are born with a solitary kidney [8]. ACE inhibitors may still be appropriate for these patients when hypertension or proteinuria develops, but starting doses should be halved (0.035 mg/kg) and titration intervals extended to every 3 to 4 weeks under specialist supervision.

Children on Concurrent Nephrotoxic Medications

NSAIDs (ibuprofen, naproxen) combined with ACE inhibitors create a "triple whammy" risk for acute kidney injury when a diuretic is also present. Pediatric patients using NSAIDs regularly for juvenile idiopathic arthritis need alternative analgesic strategies or closer renal monitoring [5].

Adverse Effects in the Pediatric Population

The most common adverse effects in the Soffer trial were cough (3.4%), headache (5.2%), and dizziness (2.6%) [2]. ACE inhibitor-induced cough occurs through bradykinin accumulation in bronchial tissue and affects roughly 5-10% of pediatric patients across the class [9]. The cough is dry, persistent, and typically appears within 1 to 4 weeks of initiation. It resolves within days of discontinuation.

Angioedema is rare (incidence approximately 0.1-0.2%) but life-threatening [9]. Black children have a 2- to 4-fold higher risk compared with White children, mirroring adult data from ALLHAT [10]. Parents must receive explicit counseling about facial or tongue swelling requiring emergency department evaluation.

First-dose hypotension is uncommon when starting at 0.07 mg/kg but can occur in volume-depleted patients. Children with diarrheal illness, those on diuretics, or those with restricted sodium intake face higher risk. Holding lisinopril during acute gastroenteritis is a standard sick-day rule.

Growth velocity should be tracked at each visit. No evidence links ACE inhibitors to growth impairment, but the clinical practice of monitoring ensures any theoretical concern is caught. The AAP guideline recommends plotting height velocity at standard intervals regardless of antihypertensive choice [3].

Drug Interactions Relevant to Pediatric Patients

Potassium-sparing diuretics (spironolactone, amiloride) combined with lisinopril increase hyperkalemia risk substantially. If both are required (as in some nephrotic syndrome protocols), potassium should be checked weekly during co-titration.

Trimethoprim-sulfamethoxazole, commonly prescribed for urinary tract infections in children, also raises serum potassium through epithelial sodium channel blockade [5]. A child on stable lisinopril who starts a 10-day course of TMP-SMX should have potassium checked at day 5 to 7.

Lithium clearance decreases with ACE inhibitor coadministration. Though lithium use in children under 12 is uncommon, adolescents with bipolar disorder on lithium require level monitoring if lisinopril is added.

Transitioning from IV to Oral Therapy

Hospitalized pediatric patients started on IV enalaprilat (the only IV ACE inhibitor available) transition to oral lisinopril once hemodynamically stable and tolerating oral intake. The conversion is not straightforward because enalaprilat is the active diacid form while lisinopril requires no hepatic activation. A rough equivalence: enalaprilat 0.01 mg/kg IV converts to lisinopril 0.07-0.1 mg/kg orally, accounting for the 25% oral bioavailability of lisinopril [1].

When to Refer vs. Manage in Primary Care

Primary care clinicians can initiate and titrate lisinopril for stage 1 hypertension in children aged 6 and older with normal renal function and no secondary hypertension features. Referral to pediatric nephrology or cardiology is indicated for any of the following scenarios: age under 6, GFR below 60 mL/min/1.73 m², suspected secondary hypertension (abrupt onset, stage 2 severity, or abnormal renal ultrasound), need for multiple antihypertensive agents, or proteinuria [3].

The evaluation workup before starting any antihypertensive in a child must include renal ultrasound with Doppler to exclude renovascular disease, urinalysis, comprehensive metabolic panel, lipid panel, and echocardiogram if stage 2 hypertension is present [3]. Skipping this workup risks masking a surgically correctable lesion like renal artery stenosis or coarctation of the aorta.

Comparison with Other Pediatric ACE Inhibitors

Enalapril holds more published pediatric data than lisinopril, primarily from the cooperative studies in the 1990s [9]. Its twice-daily dosing is a disadvantage for adherence in school-aged children. Lisinopril's once-daily dosing, lack of hepatic activation (advantageous in liver disease), and linear pharmacokinetics make it a practical choice.

Captopril requires two- to three-times-daily dosing and a liquid formulation that tastes notably worse than lisinopril suspension. It remains useful in neonatal ICU settings where short half-life provides safety in unstable hemodynamics, but has no role in outpatient pediatric hypertension management for children over 6.

The 2017 AAP guideline does not preferentially recommend one ACE inhibitor over another for pediatric hypertension [3]. Selection depends on available formulations, dosing convenience, and local formulary coverage.

Discontinuation and Rebound Considerations

ACE inhibitors do not cause rebound hypertension upon discontinuation, unlike clonidine or beta-blockers [5]. If blood pressure normalizes and the underlying etiology resolves (e.g., obesity-related hypertension after sustained weight loss), a supervised taper over 2 to 4 weeks followed by ambulatory blood pressure monitoring (ABPM) at 4 weeks post-discontinuation is appropriate.

ABPM is the gold standard for confirming normotension off medication. Office readings alone miss white-coat effects and masked hypertension, which occur in 10-15% of pediatric patients [3]. A 24-hour ABPM showing mean systolic and diastolic values below the 95th percentile with less than 25% nocturnal load confirms successful discontinuation.